PAREXEL Makes an Acquisition

PAREXEL (NASDAQ: PRXL  ) has purchased a complementary asset. The company announced it bought the entirety of HERON Group, a life sciences consultancy that according to PAREXEL "provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle of their products."

The immediate cost of the acquisition was $24 million, which was funded through PAREXEL's existing cash resources. The company might pay an additional $14.2 million over the next 26 months if HERON meets certain financial targets.

HERON was established in 1999, is headquartered in Luton, U.K., and employs around 140 people. Prior to the PAREXEL acquisition, it was privately owned.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2398670, ~/Articles/ArticleHandler.aspx, 8/22/2014 6:20:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement